W
WAVEMAN · COMPANY
IMVT · Immunovant, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475
← ALL COMPANIES

IMVT

Immunovant, Inc.
PHARMA & BIOTECH · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CIK 0001764013
FORM 144 · 4☆ WATCH
INSIDER NET · 180D
-$14.2M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
114
13F, latest reported quarter
REVENUE GROWTH
-
XBRL, annual
NET MARGIN
-
CONVERSIONS · 180D
13
codes C/M, not in net · $8.8M priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$14.2M over 180 days
-$4.5M over 90 days
below 86% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
114 funds added or opened last quarter
more than 70% of Pharma & Biotech
REVENUE
no revenue reported in any filing
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
7.9% of shares outstanding short · 18.5 days to cover · settled 2026-07-31
more than 68% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$14.2M across 8 people in 180 days.
114 funds added or opened positions in the latest 13F quarter, of 229 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +162.0%
+162.0%12M
-2%+65%+132%+198%2025-092025-102025-122026-032026-052026-072026-09 2025-12-12 · Roivant Sciences Ltd. bought $350.0M2026-05-28 · Fromkin Andrew J. sold $7.1M2026-06-26 · Stout Jay S sold $1.3M2026-04-23 · Girao Tiago sold $763.0K2026-06-26 · Van Tuyl Christopher sold $572.2K2026-06-26 · Gloria Melanie sold $563.1K2025-12-01 · Fromkin Andrew J. sold $447.8K2026-06-26 · Girao Tiago sold $384.6K2026-05-28 · Fromkin Andrew J. sold $374.8K2026-04-02 · Venker Eric sold $308.2K2025-12-01 · Hughes Douglas J. sold $302.9K2026-07-23 · Girao Tiago sold $263.0K2026-06-26 · Stout Jay S sold $261.8K2025-11-20 · Gloria Melanie sold $241.3K2025-12-18 · Van Tuyl Christopher sold $228.4K2026-04-08 · Gloria Melanie sold $216.6K2026-04-08 · Stout Jay S sold $213.9K2026-05-20 · Pande Atul sold $192.0K2026-08-20 · Gloria Melanie sold $135.0K2026-04-08 · Van Tuyl Christopher sold $128.2K2026-07-02 · Venker Eric sold $119.0K2026-06-26 · Gloria Melanie sold $115.5K2026-06-26 · Van Tuyl Christopher sold $110.7K2026-07-23 · Stout Jay S sold $110.5K2026-06-18 · Van Tuyl Christopher sold $93.2K2026-04-23 · Stout Jay S sold $81.6K2026-07-08 · Gloria Melanie sold $76.3K2026-07-08 · Stout Jay S sold $75.3K2026-03-18 · Van Tuyl Christopher sold $71.8K2025-12-01 · Fromkin Andrew J. sold $69.4K2026-05-01 · Susman Robert Graham sold $68.0K2026-08-28 · Pande Atul sold $64.9K2025-12-18 · Van Tuyl Christopher sold $62.5K2026-07-24 · Pande Atul sold $59.7K2026-06-26 · Pande Atul sold $57.0K2025-11-20 · Gloria Melanie sold $56.9K2026-05-20 · Gloria Melanie sold $55.9K2026-07-08 · Stout Jay S sold $55.3K2026-01-21 · Stout Jay S sold $51.5K2026-06-15 · Pande Atul sold $51.0K2025-10-22 · Geffner Michael sold $49.4K2025-10-22 · Stout Jay S sold $48.0K2026-06-26 · TIAGO GIRAO filed to sell $384.6K2026-06-26 · MELANIE GLORIA filed to sell $678.6K2026-06-26 · CHRIS ADAIR VAN TUYL filed to sell $682.8K2026-06-26 · JAY S STOUT filed to sell $1.5M
INSIDER BUYINSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $14.2M sold by insiders over 180 days, 114 funds added last quarter, $3.3M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Immunovant, Inc. insiders sold a net $14.2M of stock across 261 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER
FILED
SHARES
VALUE
Pande Atul
Director
SELL
2026-08-28
1,500.0
$64.9K
Gloria Melanie
Chief Operating Officer
SELL
2026-08-20
3,056.0
$135.0K
Pande Atul
Director
SELL
2026-07-24
1,500.0
$59.7K
Girao Tiago
Chief Financial Officer
SELL
2026-07-23
6,798.0
$263.0K
Stout Jay S
Chief Technology Officer
SELL
2026-07-23
2,857.0
$110.5K
261 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 256 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
FMR LLC
16,186,469.0 sh
$623.7M
Deep Track Capital, LP
9,341,151.0 sh
$359.9M
BlackRock, Inc.
7,180,897.0 sh
$276.7M
FARALLON CAPITAL MANAGEMENT, L.L.C.
5,805,000.0 sh
$223.7M
BAKER BROS. ADVISORS LP
5,435,220.0 sh
$209.4M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
TIAGO GIRAO
FILED 2026-06-26
$384.6K
MELANIE GLORIA
FILED 2026-06-26
$678.6K
CHRIS ADAIR VAN TUYL
FILED 2026-06-26
$682.8K
JAY S STOUT
FILED 2026-06-26
$1.5M
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Global Endurance Portfolio
$724.5K POSITION · AS OF 2026-03-31
4.7%
Inception Portfolio
$6.3M POSITION · AS OF 2026-03-31
2.7%
EQ/Morgan Stanley Small Cap Growth Portfolio
$5.2M POSITION · AS OF 2026-03-31
1.3%
Global X Guru Index ETF
$648.4K POSITION · AS OF 2026-04-30
1.1%
State Street(R) SPDR(R) S&P(R) Biotech ETF
$63.8M POSITION · AS OF 2026-03-31
0.9%
Research Affiliates Deletions ETF
$281.2K POSITION · AS OF 2026-03-31
0.8%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2026-032025-032024-032023-03
NET INCOME$-505.6M$-413.8M$-259.3M$-211.0M
EPS (DILUTED)-2.77-2.73-1.88-1.71
OPERATING CASH FLOW$-407.3M$-375.9M$-214.2M$-188.2M
CASH$902.1M$714.0M$635.4M$376.5M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-04 ALL SYSTEMS LIVE FOR MACHINES →